Evidence map›Paper›PMID 42388662›Full record

ArticleTransplant international : official journal of the European Society for Organ Transplantation2026

Impact of pre-transplantation exposure to immunosuppressive agents on lung transplant outcomes in interstitial lung disease.

Karim Tazibet, Vincent Bunel, Hervé Mal, Tiphaine Goletto, Pierre Halitim, Lise Morer, Domitille Mouren, Mathilde Salpin, Adèle Sandot, Gaëlle Weisenburger and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplant international : official journal of the European Society for Organ Transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Karim TazibetService de Pneumologie et Transplantation Pulmonaire, AP-HP, Hôpital Bichat, Paris, France.
Vincent BunelService de Pneumologie et Transplantation Pulmonaire, AP-HP, Hôpital Bichat, Paris, France.
Hervé MalService de Pneumologie et Transplantation Pulmonaire, AP-HP, Hôpital Bichat, Paris, France.
Tiphaine GolettoService de Pneumologie et Transplantation Pulmonaire, AP-HP, Hôpital Bichat, Paris, France.
Pierre HalitimService de Pneumologie et Transplantation Pulmonaire, AP-HP, Hôpital Bichat, Paris, France.
Lise MorerService de Pneumologie et Transplantation Pulmonaire, AP-HP, Hôpital Bichat, Paris, France.
Domitille MourenService de Pneumologie et Transplantation Pulmonaire, AP-HP, Hôpital Bichat, Paris, France.
Mathilde SalpinService de Pneumologie et Transplantation Pulmonaire, AP-HP, Hôpital Bichat, Paris, France.
Adèle SandotService de Pneumologie et Transplantation Pulmonaire, AP-HP, Hôpital Bichat, Paris, France.
Gaëlle WeisenburgerService de Pneumologie et Transplantation Pulmonaire, AP-HP, Hôpital Bichat, Paris, France.
Philippe MontraversService de Réanimation Chirurgicale, AP-HP, Hôpital Bichat, Paris, France.
Enora AtchadeService de Réanimation Chirurgicale, AP-HP, Hôpital Bichat, Paris, France.
Sébastien TanakaService de Réanimation Chirurgicale, AP-HP, Hôpital Bichat, Paris, France.
Justine FrijaService de Physiologie, AP-HP, Hôpital Bichat, Paris, France.
Linda HajoujiService de Réadaptation Respiratoire, AP-HP, Hôpital Bichat, Paris, France.
Yves CastierService de Chirurgie Vasculaire et Thoracique, AP-HP, Hôpital Bichat, Paris, France.
Pierre MordantService de Chirurgie Vasculaire et Thoracique, AP-HP, Hôpital Bichat, Paris, France.
Bruno CrestaniService de Pneumologie et Transplantation Pulmonaire, AP-HP, Hôpital Bichat, Paris, France.
Raphaël BorieService de Pneumologie et Transplantation Pulmonaire, AP-HP, Hôpital Bichat, Paris, France.
Kinan El HusseiniService de Pneumologie et Transplantation Pulmonaire, AP-HP, Hôpital Bichat, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibrosing interstitial lung diseases (ILDs) are the leading cause of lung transplantation (LTx), with worse results than other indications. We hypothesised that exposure to non-steroidal immunosuppressive agents (IAs) in the year preceding LTx for ILD may result in poorer early outcomes. We retrospectively analysed adults who underwent LTx for ILD from April 2011 to June 2024 in our institution and compared patients who received IA within 1 year before LTx to those who did not (systemic steroids exposure was used to adjust analysis). The primary outcome was 12-month retransplantation-free survival. Among 209 patients included, 76 (36%) had received IA within 1 year of LTx, and these patients had significantly worse 12-month retransplantation-free survival on multivariate analysis (62% vs. 80%; HR 1.99, 95%CI [1.11-3.56], p = 0.022); IA exposure increased the odds of grade 3 PGD (OR 3.20 [1.42-7.45], p = 0.005), bronchovascular fistula (OR 9.43, 95% CI [1.48-183], p = 0.042), pneumonia episodes in the first 6 months (median 2 [IQR 1-4] vs. 1 [0.5-2.5], p = 0.001), cytomegalovirus viremia under prophylaxis (21% vs. 5.2%, p = 0.005) and incidence of ganciclovir-resistant cytomegalovirus (14% vs. 3.2%, p = 0.021). In conclusion, IA exposure in the year before LTx leads to early complications and worse 12-month survival.

Indexed as

Immunosuppressive AgentsLung Diseases, InterstitialLung TransplantationAdultFemaleGraft RejectionHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeImmunosuppressive Agentscorticosteroid therapyimmunosuppressantsinterstitial lung diseaselung transplantationselection criteria

Identifiers

PMID42388662
PMCPMC13321801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.